SKVI News 0.0155 Skinvisible Inc (SKVI)
Post# of 273310
Posted On: 04/16/2014 3:55:26 PM
Skinvisible Inc (SKVI) 0.0155 $SKVI
Skinvisible's Sunscreen Meets New FDA Guidelines for Broad Spectrum and 80 Minute Water-Resistant Claims
Marketwire - Tue Mar 25, 8:06AM CDT
Skinvisible Pharmaceuticals, Inc. (OTCBB: SKVI) (OTCQB: SKVI) is pleased to announce that it has successfully completed independent testing to validate its broad spectrum sunscreen claims according to new labeling guidelines by the Food and Drug Administration (FDA) which are designed to help reduce the incidents of skin cancer in the U.S.
Skinvisible Adds Innovative Sunless Tanning Products Available for Exclusive Licensing
ACCESSWIRE - Tue Nov 05, 8:06AM CST
Invisicare® Suppresses Odor Associated with Sunless Formulations
OTC Signal Daily Stock Watch - Skinvisible Pharmaceuticals (OTCQB: SKVI)
WorldStockWire - Mon Sep 09, 1:45AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Skinvisible Adds Additional Patent Protection to Its Topical Drug Delivery Technology
Marketwire - Wed Jun 26, 8:05AM CDT
Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) today announced that it has expanded its US patent protection for Invisicare(R), its unique topical drug delivery technology. Skinvisible has been granted US Patent Number 8,481,058 for the topical composition precursor for Invisicare with an expiry date of June 28, 2021. The patent issued by the United States Patent and Trademark Office (USPTO) is a division of Skinvisible's US patent "Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using." This new patent expands Skinvisible's patent portfolio to fourteen US and international patents and is one of a series of five patents (including Skinvisible's initial product patent) granted in the United States specifically protecting Invisicare and the products formulated with it.
Skinvisible's Sunscreen Meets New FDA Guidelines for Broad Spectrum and 80 Minute Water-Resistant Claims
Marketwire - Tue Mar 25, 8:06AM CDT
Skinvisible Pharmaceuticals, Inc. (OTCBB: SKVI) (OTCQB: SKVI) is pleased to announce that it has successfully completed independent testing to validate its broad spectrum sunscreen claims according to new labeling guidelines by the Food and Drug Administration (FDA) which are designed to help reduce the incidents of skin cancer in the U.S.
Skinvisible Adds Innovative Sunless Tanning Products Available for Exclusive Licensing
ACCESSWIRE - Tue Nov 05, 8:06AM CST
Invisicare® Suppresses Odor Associated with Sunless Formulations
OTC Signal Daily Stock Watch - Skinvisible Pharmaceuticals (OTCQB: SKVI)
WorldStockWire - Mon Sep 09, 1:45AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Skinvisible Adds Additional Patent Protection to Its Topical Drug Delivery Technology
Marketwire - Wed Jun 26, 8:05AM CDT
Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) today announced that it has expanded its US patent protection for Invisicare(R), its unique topical drug delivery technology. Skinvisible has been granted US Patent Number 8,481,058 for the topical composition precursor for Invisicare with an expiry date of June 28, 2021. The patent issued by the United States Patent and Trademark Office (USPTO) is a division of Skinvisible's US patent "Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using." This new patent expands Skinvisible's patent portfolio to fourteen US and international patents and is one of a series of five patents (including Skinvisible's initial product patent) granted in the United States specifically protecting Invisicare and the products formulated with it.
(0)
(0)